ProQR Therapeutics NV (PRQR) was Initiated by Chardan Capital Markets to “Neutral” and the brokerage firm has set the Price Target at $4.50. Chardan Capital Markets advised their investors in a research report released on Jun 20, 2016.
ProQR Therapeutics NV (PRQR) witnessed a volatile trading activity on Friday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $4.78 and reached the intraday high at $4.94. The bulls started the profit booking and pushed the shares to intraday low of $4.65. The trading session was marked by a volume range of 24,725 shares exchanging hands. The 52-week high of the shares is $20.05 and the 52-week low is $3.48. The market cap of the company stands at $115 M and there are 2,33,45,965 shares in public circulation.
ProQR Therapeutics N.V. (ProQR) formerly ProQR Therapeutics B.V. is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of Ribo Nucleic Acid-based therapeutics for the treatment of severe genetic disorders. Utilizing its Ribo Nucleic Acid (RNA) repair technologies the Company is developing a pipeline in severe genetic disorders such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA). The Company designs its therapeutic candidates to specifically target and repair the defective messenger RNA or Messenger Ribonucleic Acid (mRNA) that is transcribed from a mutated gene in order to restore the expression and function of normal or wild-type protein. The Company’s product candidates include QR-010 and QR-110.